Pharma●Sherpa

Guiding drug development along the treacherous path toward the future

By Craig Lipset

Pages

  • Home
  • About Craig

Wednesday, December 3, 2008

Financial Times: Goldman unveils plans for pharma research funding

Goldman unveils plans for pharma research funding -- at FT.com

Interesting and creative new model proposed for managing both cost and risk in drug development. Will it work?
Posted by The PharmaSherpa at 9:03 PM

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Search

Subscribe

Posts
Atom
Posts
Comments
Atom
Comments

Disclaimer

The views expressed are those of the author and do not reflect those of past or present employers.

Upcoming Events

  • Sep 20-22 Central Labs [Boston]
  • Sep 28-29 e-Patient Connections 2010 [Philadelphia]
  • Oct 6 VITAL Consumer Digital Health [San Francisco]

Social Networking

  • LinkedIn: Craig Lipset
  • Twitter: Craig Lipset
  • Social Pharmer: Craig Lipset

Archive

  • ►  2010 (12)
    • ►  August (1)
    • ►  July (1)
    • ►  June (6)
    • ►  April (1)
    • ►  March (2)
    • ►  January (1)
  • ►  2009 (6)
    • ►  December (1)
    • ►  January (5)
  • ▼  2008 (13)
    • ▼  December (8)
      • Do Clinical Trials Take "Immoral Advantage of Pati...
      • An Example of What is Not Innovation -- Uncontroll...
      • All Knowledge Begins With The Beginner's Mind
      • Consortia -- Pre-Competitive Is In the Eye of the ...
      • Dude Where’s My Bailout: US- and UK-biotech edition
      • More attention in the news: Health2.0 Patients as ...
      • In the news: Patient-led drug trials defy medical...
      • Financial Times: Goldman unveils plans for pharma ...
    • ►  November (5)

Other Links

  • Progressive Management
Awesome Inc. theme. Powered by Blogger.